Nonsteroidal anti-inflammatory drugs and their risk: A story still in development

Arthritis Research and Therapy

Volumn 15, Issue SUPPL 3, 2013, Pages

  Simon, Lee S ^a  

^a SDG LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROTON PUMP INHIBITOR; SALICYLIC ACID DERIVATIVE;

ABDOMINAL PAIN; BLEEDING; CHRONIC PAIN; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG HALF LIFE; DYSMENORRHEA; EDITORIAL; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; KIDNEY FAILURE; LONG TERM EXPOSURE; OSTEOARTHRITIS; POSTOPERATIVE PAIN; RHEUMATOID ARTHRITIS; RISK; ARTHRALGIA; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; GASTROINTESTINAL DISEASE; KIDNEY DISEASE; LIVER DISEASE; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRALGIA; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; DICLOFENAC; GASTROINTESTINAL DISEASES; HUMANS; KIDNEY DISEASES; LIVER DISEASES; OSTEOARTHRITIS; RISK FACTORS;

EID: 84880733833     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4173     Document Type: Editorial

References (20)

1. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs: differences and similarities. N Engl J Med 1991, 324:1716-1725. 10.1056/NEJM199106133242407, 2034249.
2. Furst DE. Are there differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugs. Arthritis Rheum 1994, 37:1-9. 10.1002/art.1780370102, 7818626.
3. Simon LS. Actions and toxicities of nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol 1996, 8:169-175. 10.1097/00002281-199605000-00001, 8796974.
4. Hawkey CJ. COX-2 inhibitors. Lancet 1999, 353:307-314. 10.1016/S0140-6736(98)12154-2, 9929039.
5. Tramèr MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000, 85:169-182. 10.1016/S0304-3959(99)00267-5, 10692616.
6. Hawkey CJ. Cyclooxygenase inhibition: between the devil and the deep blue sea. Gut 2002, 50(Suppl 3):III25-III30. 1867681, 11953329.
7. Hernández-Díaz S, Rodríguez LA. Association between nonsteroidal antiinflammatory drugs and upper gastrointestinal tract bleeding/ perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000, 160:2093-2099. 10.1001/archinte.160.14.2093, 10904451.
8. Massó González EL, Patrignani P, Tacconelli S, García Rodríguez LA. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum 2010, 62:1592-1601. 10.1002/art.27412, 20178131.
9. Lewis SC, Langman MJ, Laporte JR, Matthews JN, Rawlins MD, Wiholm BE. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 2002, 54:320-326. 10.1046/j.1365-2125.2002.01636.x, 1874428, 12236853.
10. Lanas A, García-Rodríguez LA, Arroyo MT, Gomollón F, Feu F, González-Pérez A, Zapata E, Bástida G, Rodrigo L, Santolaria S, Güell M, de Argila CM, Quintero E, Borda F, Piqué JM, Asociación Española de Gastroenterología Risk of upper gastrointestinal ulcer bleeding associated with selective cyclooxygenase- 2 inhibitors, traditional non-aspirin non-steroidal antiinflammatory drugs, aspirin and combinations. Gut 2006, 55:1731-1738. 10.1136/gut.2005.080754, 1856452, 16687434, Asociación Española de Gastroenterología.
11. García Rodríguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 2007, 132:498-506. 10.1053/j.gastro.2006.12.007, 17258728.
12. Simon LS, Grierson LM, Naseer Z, Bookman AA, Zev Shainhouse J. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain 2009, 143:238-245. 10.1016/j.pain.2009.03.008, 19380203.
13. Simon LS, Hatoum HT, Bittman RM, Archambault WT, Polisson RP. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Fam Med 1996, 28:202-208.
14. Brown TJ, Hooper L, Elliott RA, Payne K, Webb R, Roberts C, Rostom A, Symmons D. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling. Health Technol Assess 2006, 10:iii-iv. xi-xiii, 1-183.
15. Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Trye PN, Cottrell J, Mann SG, Simon TJ, Sturrock RD, Russell RI. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996, 334:1435-1439. 10.1056/NEJM199605303342204, 8618582.
16. Cullen D, Bardhan KD, Eisner M, Kogut DG, Peacock RA, Thomson JM, Hawkey CJ. Primary gastroduodenal prophylaxis with omeprazole for nonsteroidal anti-inflammatory drug users. Aliment Pharmacol Ther 1998, 12:135-140. 10.1046/j.1365-2036.1998.00288.x, 9692687.
17. Graham DY, Agrawal NM, Campbell DR, Haber MM, Collis C, Lukasik NL, Huang B, NSAID-Associated Gastric Ulcer Prevention Study Group Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebocontrolled study of misoprostol vs lansoprazole. Arch Intern Med 2002, 162:169-175. 10.1001/archinte.162.2.169, 11802750, NSAID-Associated Gastric Ulcer Prevention Study Group.
18. Hawkey CJ, Karrasch JA, Szczepañski L, Walker DG, Barkun A, Swannell AJ, Yeomans ND. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998, 338:727-734. 10.1056/NEJM199803123381105, 9494149.
19. Goldstein JL, Hochberg MC, Fort JG, Zhang Y, Hwang C, Sostek M. Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. A liment Pharmacol Ther 2010, 32:401-413.
20. Laine L, Kivitz AJ, Bello AE, Grahn AY, Taha AS. Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol 2012, 107:379-386. 10.1038/ajg.2011.443, 3321505, 22186979.